Researchers at the Montreal Heart Institute have announced results showing patients with cardiovascular disease and the appropriate genetic background benefit greatly from the new medication dalcetrapib, with a significant reduction in heart attacks, strokes, unstable angina, coronary revascularisations and cardiovascular deaths.
The team led by Drs Jean-Claude Tardif and Marie-Pierre Dubé discovered a strong association between the effects of dalcetrapib and a specific gene called ADCY9 (adenylate cyclase 9) on chromosome 16, particularly for a specific genetic variant (rs1967309).
